Who are Nasal Decongestant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ibuprofen; pseudoephedrine HCl, Naproxen Sodium & Pseudoephedrine HCl, almotriptan or pseudoephedrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nasal-decongestant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nasal Decongestant — Competitive Intelligence Brief

Nasal Decongestant (Nasal Decongestant) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic decongestant. Area: Otolaryngology / Respiratory.

marketed Sympathomimetic decongestant Alpha-adrenergic receptors (likely alpha-1) Otolaryngology / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Nasal Decongestant (Nasal Decongestant) — Engelhard Arzneimittel GmbH & Co.KG. Nasal decongestants work by constricting blood vessels in the nasal mucosa to reduce swelling and improve airflow.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Nasal Decongestant TARGET	Nasal Decongestant	Engelhard Arzneimittel GmbH & Co.KG	marketed	Sympathomimetic decongestant	Alpha-adrenergic receptors (likely alpha-1)
ibuprofen; pseudoephedrine HCl	ibuprofen; pseudoephedrine HCl	Johnson & Johnson Consumer and Personal Products Worldwide	marketed	NSAID + sympathomimetic decongestant combination	COX-1/COX-2 (ibuprofen); alpha-adrenergic receptors (pseudoephedrine)
Naproxen Sodium & Pseudoephedrine HCl	Naproxen Sodium & Pseudoephedrine HCl	Dr. Reddy's Laboratories Limited	marketed	NSAID + sympathomimetic decongestant combination	COX-1/COX-2 (naproxen); alpha-1 adrenergic receptor (pseudoephedrine)
almotriptan or pseudoephedrine	almotriptan or pseudoephedrine	Clinvest	marketed	Triptan + sympathomimetic decongestant combination	5-HT1B/1D receptors (almotriptan); alpha-adrenergic receptors (pseudoephedrine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic decongestant class)

Engelhard Arzneimittel GmbH & Co.KG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nasal Decongestant — Competitive Intelligence Brief. https://druglandscape.com/ci/nasal-decongestant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab